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Abstract
Objective—The Systemic Lupus Collaborating Clinics (SLICC) revised and validated the
American College of Rheumatology (ACR) SLE classification criteria in order to improve clinical
relevance, meet stringent methodology requirements and incorporate new knowledge in SLE
immunology.
Methods—The classification criteria were derived from a set of 702 expert-rated patient
scenarios. Recursive partitioning was used to derive an initial rule that was simplified and refined
based on SLICC physician consensus. SLICC validated the classification criteria in a new
validation sample of 690 SLE patients and controls.
Results—Seventeen criteria were identified. The SLICC criteria for SLE classification requires:
1) Fulfillment of at least four criteria, with at least one clinical criterion AND one immunologic
criterion OR 2) Lupus nephritis as the sole clinical criterion in the presence of ANA or anti-
dsDNA antibodies. In the derivation set, the SLICC classification criteria resulted in fewer
misclassifications than the current ACR classification criteria (49 versus 70, p=0.0082), had
greater sensitivity (94% versus 86%, p<0.0001) and equal specificity (92% versus 93%, p=0.39).
In the validation set, the SLICC Classification criteria resulted in fewer misclassifications (62
versus 74, p=0.24), had greater sensitivity (97% versus 83%, p<0.0001) but less specificity (84%
versus 96%, p<0.0001).
Conclusions—The new SLICC classification criteria performed well on a large set of patient
scenarios rated by experts. They require that at least one clinical criterion and one immunologic
criterion be present for a classification of SLE. Biopsy confirmed nephritis compatible with lupus
(in the presence of SLE autoantibodies) is sufficient for classification.
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease, affecting more
than 300,000 in the United States (1) and millions worldwide. To ensure that there is a
consistent definition of SLE for the purposes of research and surveillance, classification
criteria for SLE are needed. The most widely used classification criteria for SLE are those
developed by the American College of Rheumatology (ACR). These classification criteria
were published in 1982 (2) and revised by a committee in 1997 (3) to delete the LE cell
criterion and to change the immunologic criterion to include anticardiolipin antibodies. The
1982 ACR criteria have been validated (4, 5), but not the 1997 revision.
Subsequently, multiple groups employed new statistical methodology to refine SLE
classification criteria. The Cleveland Clinic weighted criteria used the application of Bayes’
theorem to develop a weighting system (6). Costenbader et al formulated the Boston
Weighted Criteria, based on the Cleveland Clinic criteria, but including antiphospholipid
antibodies and renal pathology (7). In addition, criteria set points were subtracted for
elements that might negate the diagnosis, such as negative ANA. Some criteria definitions
were revised, such as arthritis requiring objective synovitis (7). The weighted criteria were
applied by Sanchez et al. and were found to be more sensitive, but less specific (8).
An alternative statistical methodology, recursive partitioning, was used by Edworthy et al
(9). Recursive partitioning or “Classification and Regression Trees” (CART) is a computer-
intensive method used to derive a classification rule based on multiple candidate predictor
variables (10). The CART software package dichotomizes variables based on all possible
cutpoints. The best discriminating cutoff is chosen for each variable. Edworthy et al used the
same data set as the 1982 ACR criteria, but added two derived variables, a standardized
ANA and a “composite” complement variable (9). In addition, analyses were done with the
immunologic criterion divided into components (anti-dsDNA, anti-Sm, false positive test for
syphilis), and the hematologic variable divided into hemolytic anemia, thrombocytopenia
and leukopenia. Using the best discriminating criteria, this method allowed correct
classification of a majority of cases and controls.
In his 1987 methodology paper, Fries reviewed the critical procedures in developing
classification criteria for SLE to avoid circularity, that is, the avoidance of criteria that are
molded to the test data and not necessarily generalizable. The critical procedures include use
of a “gold” standard which must be established by highly experienced clinicians.
Consecutively treated patients and multiple institutions need to be used to minimize
selection bias. Control populations should be chosen to represent a realistic spectrum of
related diseases that replicate the diagnostic problems that arise in real life. The variables
must be defined with precision, because a small change in the definition for a criterion could
lead to a large change in sensitivity and specificity. Finally the proposed criteria need to be
validated on a new population (because criteria always work well in the population from
which they were developed) (11).
The Systemic Lupus International Collaborating Clinics (SLICC) is an international group
dedicated to SLE clinical research. This group produced tools that form the basis of outcome
studies in SLE today, such as the SLICC-ACR Damage Index (12). In the current study
SLICC undertook a revision of the SLE classification criteria to address multiple concerns
that have arisen since the 1982 criteria were developed. The SLICC formal assessment of
the important clinical manifestations of SLE and limitations of the 1982 ACR criteria is
summarized in the journal: Lupus (13). Concerns about the clinical criteria in the current
ACR classification including: possible duplication of highly correlated cutaneous lupus
terms (such as malar rash and photosensitivity) and the absence of inclusion of many other
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lupus cutaneous manifestations; omission of many SLE neurologic manifestations; and the
need to utilize new standards in the quantification of urine protein. Concerns about the
immunologic criterion included the omission of low complement, and the need to include
new knowledge on antiphospholipid antibodies. Most of all, there were concerns about
patients without any immunologic criteria being classified as SLE (an autoantibody-
mediated disease). Indeed clinical trials have had to add the requirement for the presence of
a SLE autoantibody when recruiting patients to optimize the likelihood of response to
immunosuppressive therapy (14). It was felt that important control groups, including chronic
cutaneous lupus, needed to be included in a validation exercise. Therefore, we included a
number of Dermatology sites. Finally, It was felt that biopsy confirmed nephritis compatible
with SLE (in the presence of lupus autoantibodies) was so indisputably representative of the
disease that it should be considered sufficient as a “stand alone” clinical criterion. The
revision exercise was conducted in accordance with the methodology requirements
summarized by Fries (11).
PATIENTS AND METHODS
DERIVATION STEP
Choosing a set of relevant variables—An initial set of precisely defined variables to
be abstracted from medical records for each patient was determined at a SLICC meeting in
Lund, Sweden, April 25-27, 2003. At this meeting, experts in each organ system affected by
SLE gave a formal presentation, reviewing the current (1997) ACR classification criteria,
and other classification approaches to that organ system. The list of variables was further
refined at a meeting of SLICC in Orlando, Florida in October 2003, later published in the
journal Lupus (13, 15-23).
Obtaining the example patient scenarios—Each participating center was asked to
submit data on 10 to 12 consecutive patients with a clinical diagnosis of SLE and 12 to 15
controls. The controls were to consist of consecutively seen patients with one of the
following diagnoses: rheumatoid arthritis, myositis, chronic cutaneous lupus,
undifferentiated connective tissue disease, vasculitis, primary antiphospholipid antibody
syndrome, scleroderma, fibromyalgia, Sjögren syndrome, rosacea, psoriasis, sarcoidosis and
juvenile idiopathic arthritis. Because it was recognized that important control groups ,
including chronic cutaneous lupus, which had not necessarily been part of previous efforts,
needed to be represented, cases were also contributed by a number of dermatologists.
Arriving at a consensus diagnosis for each patient scenario—The information
regarding each patient was summarized in a standardized short narrative, and these were
sent to 32 rheumatologists from the SLICC group. SLICC physicians classifying patients
were unaware of the submitting physician's diagnosis. These clinicians then classified each
patient as having, or not having, SLE. If 80% of the rheumatologists agreed on the
classification, that diagnosis was considered the “consensus” diagnosis. Those scenarios that
did not reach consensus in this way were later discussed by a panel of 5, and if 4/5 agreed on
a classification, that diagnosis was also considered the “consensus” diagnosis.
Identifying a reduced set of variables to consider for the classification rule—A
SLICC subcommittee (GSA, PF, CG, JM and GM) examined dozens of variables. The
subcommittee reviewed extensive logistic regression analyses and decision tree analyses in
order to use a data driven approach to the selection and combination of items with about 40
different combinations of over 20 items. Although a few clinically important items were
kept in the final criteria because of their clinical importance (such as low complement), the
selection of items was strongly influenced by logistic regression analyses in both the
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selection and the elimination of many items. Thus the final selection of items was data
driven but refined by consensus view. These variables were then considered the candidate
predictor variables for the recursive partitioning analyses.
Using recursive partitioning to derive a relatively simple classification rule—
Using recursive partitioning (CART software package) patients were divided into two
groups based on all candidate variables. The resulting partitions were evaluated. The
partition that resulted in the best separation of SLE cases from non-cases was chosen for the
first split of the tree. At subsequent steps, the procedure was repeated within the subgroups
created by previous splits. The algorithm identified subgroups of patients defined by
predictor variables which were relatively homogeneous with respect to SLE diagnosis. The
resulting subgroups could then be identified using a relatively simple rule. This approach
was applied by the SLICC subcommittee (Chair, Graciela S. Alarcón, MD, MPH) using the
candidate set of variables to result in a preliminary data-driven classification rule, with the
requirement of at least one clinical and one immunologic variable being necessary.
Refining the rule—The preliminary classification rule was discussed at three meetings of
SLICC members in 2008. These small group meetings, organized with the help of Dr. Ian
Bruce and Dr. David Isenberg, allowed intense discussions of the criteria deficiencies.
Patients who were misclassified by the rule were used to stimulate discussions regarding
how the rule or definitions of the variables could be changed to improve the classification
rule. In the final SLICC meeting, discussion, followed by a vote, was used to ratify
remaining items for which there was not unanimous agreement. As a result of this step we:
1) excluded anti-C1q as an immunologic criterion; 2) excluded a “constitutional” clinical
criterion of fever and lymphadenopathy; and 3) included joint line tenderness with morning
stiffness under the “arthritis” criterion.
VALIDATION STEP
Obtaining the validation patient scenarios—To assess the performance of the new
classification rule, we obtained detailed data regarding a new set of 690 additional patients.
Sites were again asked to submit information on patients diagnosed with SLE, and on an
approximately equal number of controls with the following diagnoses: rheumatoid arthritis,
undifferentiated connective tissue disease, primary antiphospholipid antibody syndrome,
vasculitis, chronic cutaneous lupus, scleroderma, Sjögren syndrome, myositis, psoriasis,
fibromyalgia, alopecia areata and sarcoidosis. These data were collected on standardized
case report forms and sent to the coordinating site. Information included a demographics
summary, a clinical scenario, specification of ACR criteria that were met and not met,
specification of SLICC criteria met and not met, auto-antibody titers and complement titers.
In addition, serum from each patient was sent to the coordinating site and analyzed at the
Rheumatology Diagnostic Laboratory (Los Angeles, CA) for anti-dsDNA by ELISA,
Crithidia and Farr assays, anti-Smith antibody and complement C3 and C4 levels. A second
set of blood samples were tested for antiphospholipid antibodies (lupus anticoagulant,
ELISA assay for IgG, IgM and IgA isotypes of anticardiolipin antibodies and anti-beta2
glycoprotein1 antibodies) at the laboratory of Joan Merrill, M.D. (Oklahoma Medical
Research Foundation). Direct Coombs was done at each center's own laboratory or at Quest
Diagnostics. A short description of each patient (“patient scenario”) was generated
containing the submitted information and the updated auto-antibody and complement
profiles.
Arriving at a consensus diagnosis for each patient—These patient scenarios were
submitted to participating SLICC members for rating as either SLE or not SLE. Twelve
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SLICC members rated all 690 scenarios, and three SLICC members rated some but not all
scenarios. Those scenarios which did not reach 80% consensus in the initial rating process
were edited for clarity, and re-rated by the larger group of 33 SLICC physicians. SLICC
physicians classifying patients were unaware of the submitting physician's diagnosis. More
than 80% consensus was achieved on 615 cases while 75 cases remained without a
consensus diagnosis of SLE or not SLE. After this second round of ratings, the 75
nonconsensus scenarios were classified as either SLE or not SLE based on the majority
opinion.
Statistical Methods—The Kappa statistic was used to quantify the chance-adjusted
degree of agreement between the classification rules and the gold standard rating based on
the majority opinions of the raters. McNemar's test was used to assess whether there was a
significant difference between the current ACR Revised Classification criteria and the
SLICC Classification criteria with respect to accuracy.
RESULTS
In the derivation step, abstracted data from a total of 716 patients were submitted from 25
different sites. While most sites submitted data on more than 20 patients, two sites submitted
fewer than 10 patients, and one site (Johns Hopkins) submitted data on 171 patients. The
716 scenarios that were contributed had the following diagnoses at their site: systemic lupus
erythematosus 293, rheumatoid arthritis 119, myositis 55, chronic cutaneous lupus 50,
undifferentiated connective tissue disease 44, vasculitis 37, primary antiphospholipid
antibody syndrome 33, scleroderma 28, fibromyalgia 25, Sjögren syndrome 15, rosacea 8,
psoriasis 7, sarcoidosis 1, and juvenile idiopathic arthritis 1.
Each submitted patient was reviewed by 26-32 clinicians. The results of the initial
classification are summarized in Table 1. For 262 (36.6%) of the 716 patients, 80% or more
of the physicians diagnosed the patient as having SLE. For 354 (49.4%) patients, 80% or
more diagnosed the patient as not having SLE. Thus, there was 80% or more agreement for
616 (86%) of the scenarios (with respect to SLE status). These classifications agreed with
the submitting diagnosis 561 (91%) of the time.
For the remaining 100 (14%) patients, there was less agreement regarding the diagnosis
(Table 1). These 100 patients then underwent further review and discussion by five member
panels. Eighty percent consensus was reached for 86 of these patients. Thus, ultimately a
consensus diagnosis was achieved for 702 (98%) of the 716 patients submitted for the study.
The consensus diagnosis agreed with the diagnosis of the submitting physician 95% of the
time. The analyses described below are based on these 702 patients.
Eighteen criteria that were associated with SLE diagnoses were identified and were initially
considered. These were divided into two groups: immunological and “clinical”, based on the
judgment of the SLICC subcommittee. The degrees of association between each candidate
criterion and the consensus diagnosis of SLE are shown in Table 2. Recursive portioning
was applied to this set of variables to arrive at our initial working rule. After discussion and
examination of misclassified cases, some definitions were refined, and leukopenia and
lymphopenia were combined. Table 3 provides the final list of criteria, and provides details
regarding how each criterion was ultimately defined.
Criteria need not be present concurrently. The proposed classification rule is as follows:
Classify a patient as having SLE if
Petri et al. Page 7
Arthritis Rheum. Author manuscript; available in PMC 2013 August 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
The patient satisfies four of the criteria listed in Table 3, including at least one
clinical criterion and one immunologic criterion.
OR
The patient has biopsy-proven nephritis compatible with SLE and with ANA or
anti-dsDNA antibodies.
Table 4 shows the performance of this classification rule in our derivation set of patients. In
the derivation set the proposed rule had greater sensitivity (94% versus 86%, p<0.0001) and
equal specificity (92% versus 93%, p=0.39). Using McNemar's test, we found that the
proposed rule resulted in significantly fewer misclassifications than the current ACR
classification criteria rule (p=0.0082).
To validate the proposed new rule we used data collected on 690 additional patients that
were not used to derive this rule. These patients were submitted from 15 different sites. All
sites submitted data on more than 20 patients and one site (Johns Hopkins) submitted data
on 180 patients. The 690 validation patient scenarios that were contributed had the following
diagnoses at the contributing site: systemic lupus erythematosus 337, rheumatoid arthritis
118, undifferentiated connective tissue disease 89, primary antiphospholipid antibody
syndrome 30, vasculitis 29, chronic cutaneous lupus 24, scleroderma 20, Sjögren syndrome
15, myositis 14, psoriasis 8, fibromyalgia 4, alopecia areata 1, and sarcoidosis 1.
Eighty percent agreement was achieved for 590 (86%) of the patient scenarios during the
first round of rating. The 100 scenarios that did not achieve 80% agreement during the first
round of ratings were then sent to a larger group of SLICC members for the second round of
rating. Table 5 shows the degree of agreement achieved for all 690 scenarios based on both
rounds of rating. Note that 80% or more agreement was achieved on whether the case was
SLE or not SLE for all but 75 (11%) of the scenarios. The majority rule rating agreed with
the submitting diagnosis (with respect to SLE status) 93% of the time.
Table 6 shows the sensitivity and specificity of each classification rule relative to the
classification made by the majority of raters in the validation patients. The SLICC rule was
more sensitive (97% versus 83%, p<0.0001) than the current (1997) ACR rule, but less
specific (84% versus 96%, p<0.0001). Overall the SLICC rule performed better than the
ACR rule, misclassifying 12 fewer patients and having a higher Kappa. The difference
between the rules, however, was not statistically significant (p=0.24).
If we restrict the analysis to those 615 scenarios that achieved 80% or more agreement after
the second round of rating, the sensitivity and specificity of the SLICC criteria were found
to be 98% and 91% respectively. In contrast, in this subset of scenarios, the sensitivity and
specificity of the ACR criteria were 88% and 98% respectively, and these reflect 9 more
misclassifications.
DISCUSSION
The SLICC classification criteria for SLE represent an eight year effort of clinical review,
consensus and statistical analyses. The final criteria were derived using recursive
partitioning (“tree-based” approach), but were simplified to a simple rule: “lupus nephritis”
(in the presence of at least one of the immunologic variables indicated) as a “stand alone”
criterion, OR four criteria (with one having to be a clinical criterion and one having to be an
immunologic criterion). The requirement for at least ONE clinical and ONE immunologic
criterion reflects the opinion of SLICC that neither clinical criteria alone nor positive
serologic tests alone should be considered SLE, as SLE is ultimately an autoantibody-driven
clinical disease.
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The clinical criteria improve on the revised ACR classification criteria in several important
ways. Malar rash and photosensitivity are not separate items, as they are largely
overlapping. One cutaneous criterion includes both acute and subacute cutaneous lupus,
whereas a separate cutaneous criterion now includes discoid rash and the many different
types of chronic cutaneous lupus not included in the current ACR classification criteria. To
employ these optimally, it is anticipated that some proposed SLE patients will require a
dermatologic consultation, and sometimes a skin biopsy. Non-scarring alopecia is included,
as it was in the original ARA criteria (24): although not specific for SLE, it performed well
in the univariate and recursive partitioning analyses, and met the bar of clinical consensus.
The arthritis criterion has been substantially redefined. First, it does not require a
radiograph: some SLE arthritis is, in fact, erosive (25). Second, joint line tenderness with 30
minutes of morning stiffness now qualifies for arthritis. Because of the overlap of
fibromyalgia and SLE in some patients, it will be necessary to confirm that there is
specifically joint line tenderness and not more diffuse allodynia. It is also essential to
underscore that for all the SLICC criteria, the clinician must be able to determine that the
cause is likely attributable to SLE and not due to another disease process or condition.
The renal criterion now includes measurement of proteinuria by the urine protein/creatinine
ratio without the requirement of a time frame for collection. This reflects acceptance that the
“spot” or random urine protein/creatinine ratio is easier to obtain than a 24 hour urine
protein (26), and that a qualitative estimate of proteinuria from a dipstick is insufficient for
clinical judgment, as it is an unreliable quantitative measure. The gold standard, however,
remains the urine protein/creatinine ratio done on a 24-hour urine collection (27).
The neurologic criterion has been substantially re-written to include a greater number of
SLE neurologic manifestations than the original ACR definition of seizures or psychosis. It
does not include all the ACR neuropsychiatric case definitions (28), due to the absence of
specificity of most of these for SLE (29).
The hematologic criteria have been split into three parts: hemolytic anemia, leukopenia/
lymphopenia and thrombocytopenia. Statistical modeling showed that it made no difference
whether “once” or “more than once” was required. Therefore, to simplify assessment, the
SLICC criteria require only one abnormal assessment (of course, the result must be due to
SLE and not other factors, such as prednisone [for lymphopenia], immunosuppressive drug
use, infection, or other causes). We accept that the cut-off range for leukopenia may need to
be amended for patients of certain ethnic groups (30).
The immunologic criterion reflects new knowledge about serologic tests in SLE and also the
concern of SLICC about the wider use of ELISA and multiplex assays (31). The ANA
criterion remains unchanged. In the old immunologic criterion, anti-dsDNA antibodies, anti-
Sm antibodies, lupus anticoagulant, false-positive test for syphilis, and anticardiolipin
antibodies were combined. The new SLICC classification criteria has split these features
into separate criteria, so that each may contribute to classification. The new anti-dsDNA
antibody criterion, however, requires a stricter cut-off for ELISA assays. Anti-Sm antibody
is now an individual criterion. The new antiphospholipid antibody criterion now includes
anti-β2 glycoprotein I antibodies. The anticardiolipin definition excludes non-specific “low”
levels (which were included in the revised ACR criteria) (3). IgG, IgM, or IgA isotypes are
allowed for anti-β2 glycoprotein I and anticardiolipin, reflecting new knowledge that IgA
isotypes are important in SLE (32).
Upon SLICC consensus, even though it did not improve the statistical modeling, we
included low complement, defined by C3, C4, or total hemolytic complement, reflecting the
contribution of complement to disease pathogenesis.
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We included the direct Coombs (anti-globulin) test. Direct Coombs did improve statistical
modeling. To avoid “double counting”, however, it is not counted if the patient has the
clinical criterion of hemolytic anemia.
The final important aspect of the new SLICC classification criteria is that biopsy confirmed
nephritis compatible with SLE according to the International Society of Nephrology/Renal
Pathology Society (ISN/RPS) 2003 Classification of Lupus Nephritis (33), in the presence of
ANA or anti-dsDNA antibodies is now sufficient for a classification of SLE. SLICC thought
this was important in both clinical practice and for enrollment in clinical trials. It is
acknowledged that the presence of anti-dsDNA antibodies in the absence of ANA is a rare
phenomenon and may be due to laboratory error.
The SLICC classification criteria performs better than the revised ACR criteria in terms of
sensitivity, but not specificity. These criteria are meant to be clinically more relevant,
allowing the inclusion of more patients with clinically-defined lupus than using the current
ACR criteria. They will be important in clinical trials and in longitudinal observational
studies.
The SLICC classification criteria were subjected to rigorous testing. The new patient sample
used for validation consisted of 690 patients and included patients from multiple centers
with multiple diagnoses that have clinical features that overlap with lupus. In the validation
sample the SLICC classification criteria misclassified fewer cases and had higher sensitivity,
although less specificity. The difference between the ACR classification criteria and SLICC
classification criteria performance was not statistically significant. The SLICC classification
criteria have better face and content validity as they overcome many concerns with the
current criteria. In particular, the new criteria require the presence of both clinical and
serologic criteria so that patients without autoantibodies or low complement, the hallmark of
SLE, cannot be classified as having SLE. Clinical trials of lupus have had to add to their
inclusion criteria the requirement for lupus autoantibodies to overcome this deficiency (14).
The SLICC validation exercise serves as the first validation of the SLICC classification
criteria (and validates the revised ACR criteria as well) in studies involving the largest,
multicenter population sample, since the initial conception of the ACR classification criteria
for SLE. It is important to emphasize that the 1997 revision of the ACR criteria was never
validated. The ACR criteria continue to perform well compared to the current physician
diagnosis gold standard, but do not include the updated and more inclusive definitions of
variables of the SLICC criteria. The SLICC Classification Criteria provide alternative
classification criteria for use in SLE clinical care and research. The validated SLICC
Classification Criteria have gained in face validity over the revised ACR criteria and are
more in line with advancing concepts of SLE pathogenesis. It should be noted that, as with
the original revised ACR criteria, they have not been tested for purposes of diagnosis.
SLICC concludes that the new criteria retain the goal of simplicity of use, yet reflect current
knowledge of SLE obtained in the 29 years since the initial ACR criteria.
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Table 1
Degree of agreement on SLE diagnosis based on the initial ratings of 26-32 clinicians in the derivation step.
Percentage of clinicians classifying scenarios as SLE Number of derivation scenarios n=716 (%)
01 250 (34.9)
1-20 104 (14.5)
20-492 47 (6.6)
50-792 53 (7.4)
80-99 138 (19.3)
1003 124 (17.3)
Number (%) with 80% or more agreement 616 (86%)
1None of the physicians classified these scenarios as SLE.
2Shaded rows show number (%) of scenarios with <80% agreement.
3All physicians classified these scenarios as SLE.
Arthritis Rheum. Author manuscript; available in PMC 2013 August 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Petri et al. Page 14
Table 2
Sensitivity, Specificity of each individual criterion for SLE in the Derivation Sample.
Criteria
“Sensitivity”1 (n=310) “Specificity”2 (n=392)
Malar rash/photosensitive rash/acute cutaneous lupus 65.2 80.1
Discoid 19.7 93.6
Oral ulcers 44.2 92.1
Non-scarring alopecia 31.9 95.7
Arthritis 79.0 43.6
Serositis 35.2 97.2
Renal 32.9 96.4
Neurologic 5.5 99.0
Hemolytic Anemia 7.1 99.5
Leukopenia 46.4 94.8
Lymphopenia (<1.5k) 49.0 81.6
Lymphopenia (<1k) 17.0 94.7
Thrombocytopenia 13.5 98.0
ANA 33.6 96.8
Anti-dsDNA 57.1 95.9
Anti-Sm 26.1 98.7
Antiphospholipid antibody 53.6 86.0
Low Complement 59.0 92.6
1
“Sensitivity”: of those that were 80% consensus SLE, proportion (%) which satisfied the criterion.
2
“Specificity”: of those that were 80% consensus not SLE, proportion (%) that did not satisfy the criterion.
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Table 3
Clinical and Immunologic Criteria Used in the SLICC Classification Criteria.
Clinical Criteria
1. Acute cutaneous lupus
    including lupus malar rash (do not count if malar discoid)
                bullous lupus
                toxic epidermal necrolysis variant of SLE
                maculopapular lupus rash
                photosensitive lupus rash
                                in the absence of dermatomyositis
            or subacute cutaneous lupus
                (nonindurated psoriaform and/or annular polycyclic lesions that resolve without scarring, although occasionally with
postinflammatory dyspigmentation or telangiectasias)
2. Chronic cutaneous lupus
including classical discoid rash
                    localized (above the neck)
                    generalized (above and below the neck)
                hypertrophic (verrucous) lupus
                lupus panniculitis (profundus)
                mucosal lupus
                lupus erythematosus tumidus
                chillblains lupus
                discoid lupus/lichen planus overlap
3. Oral ulcers: palate
                buccal
                tongue
            or nasal ulcers
        in the absence of other causes, such as vasculitis, Behcets, infection (herpes), inflammatory bowel disease, reactive arthritis, and acidic
foods
4. Nonscarring alopecia (diffuse thinning or hair fragility with visible broken hairs)
        in the absence of other causes such as alopecia areata, drugs, iron deficiency and androgenic alopecia
5. Synovitis involving two or more joints, characterized by swelling or effusion OR tenderness in 2 or more joints and thirty minutes or more of
morning stiffness.
6. Serositis
        typical pleurisy for more than 1 day
            or pleural effusions
            or pleural rub
        typical pericardial pain (pain with recumbency improved by sitting forward) for more than 1 day
            or pericardial effusion
            or pericardial rub
            or pericarditis by EKG
                in the absence of other causes, such as infection, uremia, and Dressler's pericarditis
7. Renal
    Urine protein/creatinine (or 24 hr urine protein) representing 500 mg of protein/24 hr
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Clinical Criteria
    or
    Red blood cell casts
8. Neurologic
        seizures
        psychosis
        mononeuritis multiplex
                        in the absence of other known causes such as primary vasculitis
        myelitis
        peripheral or cranial neuropathy
                        in the absence of other known causes such as primary vasculitis, infection, and diabetes mellitus
        acute confusional state
                        in the absence of other causes, including toxic-metabolic, uremia, drugs
9. Hemolytic anemia
10. Leukopenia (< 4000/mm3 at least once)
        in the absence of other known causes such as Felty's, drugs, and portal hypertension
            OR
    Lymphopenia (< 1000/mm3 at least once)
        in the absence of other known causes such as corticosteroids, drugs and infection
11. Thrombocytopenia (<100,000/mm3) at least once
        in the absence of other known causes such as drugs, portal hypertension, and TTP
Immunological Criteria
1. ANA above laboratory reference range
2. Anti-dsDNA above laboratory reference range, except ELISA: twice above laboratory
    reference range
3. Anti-Sm
4. Antiphospholipid antibody: any of the following
    lupus anticoagulant
    false-positive RPR
    medium or high titer anticardiolipin (IgA, IgG or IgM)
    anti-β2 glycoprotein I (IgA, IgG or IgM)
5. Low complement
    low C3
    low C4
    low CH50
6. Direct Coombs test in the absence of hemolytic anemia
Criteria are cumulative and need not be present concurrently.
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Table 4
Performance of the proposed classification, compared to the current ACR criteria on the derivation sample,
based on 702 cases.
Rule
“Sensitivity”1 “Specificity”2 Misclassified Cases (number)
1997 ACR Criteria3 267/310 (86%) 365/392 (93%) 70
SLICC Criteria 292/310 (94%) 361/392 (92%) 49
1
“Sensitivity”: Of those that were 80% consensus SLE, proportion (%) correctly classified by the criteria as SLE.
2
“Specificity”: Of those that were 80% consensus not SLE, proportion (%) correctly classified by the criteria as not SLE.
3ACR criteria are based on satisfying 4 of 11 criteria.
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Table 5
Degree of agreement on SLE diagnosis based on the final ratings in the validation step.
Percentage of clinicians classifying scenarios as SLE Number of validation scenarios n=690 (%)
01 227 (33)
1-20 75 (10.8)
20-492 38 (5.5)
50-792 37 (5.4)
80-99 95 (13.7)
1003 218 (31.6)
Number (%) with 80% or more agreement 615 (89%)
1None of the physicians classified these scenarios as SLE.
2Shaded rows show number (%) of scenarios with <80% agreement.
3All physicians classified these scenarios as SLE.
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Table 6
Performance of the SLICC Classification Criteria and the ACR criteria after classifying each of the 690
patients as either SLE or not SLE based on the principle of “Majority Rules”.
Rule
“Sensitivity”1 “Specificity”2 Misclassified cases (number) Kappa
1997 ACR criteria3 290/349 (83%) 326/341 (96%) 74 0.79
SLICC Criteria 340/349 (97%) 288/341 (84%) 62 0.82
The difference between the rules in misclassification rate is not statistically significant, p=0.24.
1
“Sensitivity”: of those classified as SLE by the majority of raters, proportion (%) correctly classified by the rule as SLE.
2
“Specificity”: of those classified as not SLE by the majority of raters, proportion (%) correctly classified by the rule as not SLE.
3ACR criteria are based on satisfying 4 out of 11 criteria.
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